Wegovy (semaglutide injection and tablets) is a GLP-1 receptor agonist from Novo Nordisk. As of May 2026, it carries four FDA-approved indications: chronic weight management, cardiovascular risk reduction in adults with established CVD and overweight or obesity, treatment of noncirrhotic MASH with moderate to advanced fibrosis (accelerated approval), and a higher-dose 7.2 mg injection (Wegovy HD) approved March 2026. The Wegovy oral tablet (25 mg daily) was approved December 2025.
Coverage is more fragmented than for Ozempic because weight management has historically been excluded or restricted by many plans. The cardiovascular and MASH indications are opening new payer pathways. This guide explains what access teams, prescribers, and prior authorization coordinators need to know.
Who this is for
Pharmacy access teams, managed care liaisons, healthcare providers prescribing Wegovy, and patients navigating insurance coverage for semaglutide-based weight management, cardiovascular risk reduction, or MASH treatment.
FDA-approved indications that determine coverage
| Indication | Key trial | Approval date |
|---|---|---|
| Chronic weight management (BMI ≥30, or ≥27 with comorbidity) | STEP program | June 2021 |
| CV risk reduction in adults with CVD and overweight/obesity | SELECT | March 2024 |
| Noncirrhotic MASH with F2–F3 fibrosis (accelerated approval) | Phase 3 MASH trial | Under accelerated approval |
| Higher-dose weight management (Wegovy HD 7.2 mg) | Additional dose evaluation | March 2026 |
| Oral tablet (25 mg daily) for weight management | OASIS 4 | December 2025 |
The SELECT trial showed that Wegovy 2.4 mg reduced the risk of MACE (cardiovascular death, nonfatal MI, nonfatal stroke) by 20% versus placebo in adults with established CVD and overweight or obesity (HR 0.80, 95% CI 0.72–0.90). This cardiovascular indication is the basis for Medicare Part D coverage.
Commercial insurance coverage
Formulary placement and coverage patterns
Wegovy is covered by many employer-sponsored commercial plans, but coverage is far from universal. Key patterns:
- Fully insured group plans: Often cover Wegovy with prior authorization. Typical criteria include BMI ≥30 (or ≥27 with a qualifying comorbidity), documented participation in lifestyle modification, and step therapy requirements.
- Self-funded employer plans: Coverage is employer-specific. Some large employers have added GLP-1 benefits; others explicitly exclude weight loss medications. Check the plan's summary plan description.
- Individual and family plans: Coverage varies by state and plan tier. Some state marketplace plans limit coverage to non-GLP-1 weight loss medications.
Many insurers classify obesity treatment as a benefit exclusion even when Wegovy is FDA-approved. The cardiovascular and MASH indications may bypass weight-loss exclusions if documentation supports the covered diagnosis.
Prior authorization requirements
Most commercial plans requiring PA for Wegovy ask for:
- BMI documentation — ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, etc.).
- Lifestyle modification history — documented participation in diet and exercise counseling.
- Step therapy — some plans require prior failure on a less expensive weight loss medication (e.g., Contrave, Qsymia, or orlistat) before approving a GLP-1.
- Diagnosis-specific documentation — for the CV indication, records showing established CVD (prior MI, ischemic stroke, or symptomatic PAD). For MASH, biopsy-confirmed F2–F3 fibrosis.
UnitedHealthcare's commercial PA criteria for Wegovy (cardiovascular indication) require the patient to be 45 or older, have BMI ≥27, documented established CVD, concurrent use of statin and antiplatelet therapy unless contraindicated, and no diagnosis of diabetes (A1C ≤6.5%). Authorization is issued for 12 months.
Aetna's Medicaid and Medicare criteria require ≥5% weight loss from baseline documented at renewal for continued coverage. These criteria illustrate how tightly plans manage reauthorization.
Medicare Part D coverage
Medicare coverage of Wegovy is indication-specific:
| Indication | Medicare Part D coverage |
|---|---|
| Weight loss alone | Not covered under current CMS rules |
| CV risk reduction (SELECT indication) | May be covered if patient meets criteria (established CVD, BMI ≥27, prescribed by enrolled Medicare provider) |
| MASH treatment | Coverage is plan-dependent and evolving |
Wegovy may be placed on a specialty tier with coinsurance of 25–33%, which at the list price of approximately $1,350/month could translate to $325–$430 per month before the annual out-of-pocket cap. Under the Inflation Reduction Act, the 2026 Part D out-of-pocket maximum is $2,100.
The Medicare GLP-1 Bridge (July 2026)
On May 7, 2026, CMS announced the Medicare GLP-1 Bridge, a temporary program running from July 1, 2026 through December 31, 2027. Key details:
- Eligible medications: Wegovy injection (all doses, 0.25 mg through 7.2 mg) and Wegovy tablets are included. Zepbound (KwikPen formulation) and Foundayo (oral) are also eligible. Ozempic is not included because it is not approved for weight management.
- Copay: $50 per month for eligible beneficiaries.
- Manufacturer price: Participating manufacturers provide drugs at a net price of $245 per monthly supply.
- Eligibility: Beneficiaries must have a diagnosis of obesity (BMI ≥30) or overweight (BMI ≥27) with qualifying conditions such as heart failure, chronic kidney disease, prediabetes, prior heart attack, prior stroke, or symptomatic peripheral artery disease.
- Requirements: Provider prescription, prior authorization, and CMS eligibility verification.
- Availability: Nationwide across all states and territories.
This program is separate from standard Part D coverage and does not change the existing coverage rules for Wegovy's cardiovascular or MASH indications. Wegovy will continue to be available for eligible Medicare beneficiaries through normal Part D benefits for the cardiovascular risk reduction indication.
According to an NPR report citing GoodRx research, approximately 12 million commercially insured people lost coverage for Wegovy between 2025 and 2026 as plans tightened GLP-1 coverage for weight management. The Medicare GLP-1 Bridge is a partial response to this access gap for the Medicare population.
Medicaid coverage by state
Medicaid coverage for Wegovy varies significantly:
| State category | Examples | Details |
|---|---|---|
| Covers GLP-1 for obesity with PA | New York, California, Massachusetts, Minnesota | Strict BMI and comorbidity criteria; PA required |
| Limited AOM coverage (non-GLP-1 only) | Illinois, Pennsylvania, Ohio | Cover older weight loss medications but exclude GLP-1s for obesity |
| No weight loss medication coverage | Texas, Florida, Georgia, Tennessee | Exclude all drugs prescribed primarily for weight loss |
| Coverage under review | Virginia, North Carolina, Arizona | Legislation or Medicaid policy changes pending |
Medi-Cal MASH coverage update (April 2026)
Effective April 1, 2026, Medi-Cal no longer requires prior authorization for Wegovy when prescribed for noncirrhotic MASH. Claims must include ICD-10-CM codes K76.0 and/or K75.8. PA is still required for all other Wegovy diagnoses. Weight-loss-only prescriptions remain excluded from Medi-Cal coverage.
California Medi-Cal removed GLP-1 coverage for weight-loss-only prescriptions effective January 1, 2026. Wegovy is still covered for MASH and cardiovascular indications with PA. Pennsylvania Medicaid requires dose titration to semaglutide 2 mg (Ozempic maximum) before approving Wegovy 2.4 mg, plus documentation of therapeutic failure on the maximum tolerated dose.
Savings and assistance programs
| Program | Monthly cost | Eligibility |
|---|---|---|
| NovoCare Savings Card (commercial) | As little as $25/month (max savings $100/month) | Commercial insurance; government beneficiaries excluded |
| NovoCare Pharmacy self-pay intro | $199/month for first 2 months (0.25 mg, 0.5 mg through June 2026) | Uninsured or cash-pay patients |
| NovoCare Pharmacy self-pay ongoing | $349/month (0.25–2.4 mg), $399/month (Wegovy HD 7.2 mg) | Uninsured or cash-pay patients |
| Wegovy tablet self-pay | $149/month (1.5 mg, 4 mg through August 2026) | Uninsured or cash-pay patients |
| Novo Nordisk PAP | Free | Uninsured patients at or below 200% FPL; most Medicare patients excluded in 2026 |
Patients can activate the savings card by texting SAVE to 83757 or visiting WegovySavings.com.
What changed recently
- February 2026: Novo Nordisk announced a significant US list price reduction for Wegovy, Ozempic, and Rybelsus, building on continued access expansion efforts.
- March 2026: FDA approved Wegovy HD 7.2 mg injection via the National Priority Voucher program (54-day review).
- December 2025: FDA approved Wegovy oral tablets (25 mg daily), the first oral GLP-1 for chronic weight management.
- January 2026: Novo Nordisk updated its Patient Assistance Program to exclude most Medicare Part D patients, citing widespread formulary coverage.
What to monitor
- IRA price negotiation: Semaglutide (Ozempic/Wegovy) was selected for the second round of Medicare drug price negotiations in January 2025. Negotiated prices would take effect in 2027.
- Medicare GLP-1 Bridge rollout: Monitor CMS guidance on the July 2026 launch, eligible populations, and participating Part D plans.
- State Medicaid policy changes: Multiple states are reviewing GLP-1 coverage for obesity. Legislation is pending in Virginia, North Carolina, and Arizona as of early 2026.
- MASH confirmatory trial: The Wegovy MASH indication was granted under accelerated approval. Continued approval depends on confirmatory clinical benefit data. Monitor FDA announcements for any label updates.
- Commercial coverage contraction: GoodRx data show 12 million people lost Wegovy coverage between 2025 and 2026. Monitor employer plan changes during open enrollment.
Sources
- FDA, Wegovy prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s029lbl.pdf
- FDA, Wegovy CV risk reduction approval: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- FDA, Wegovy HD 7.2 mg approval: https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide
- Novo Nordisk, Wegovy PA support: https://www.novomedlink.com/obesity/products/treatments/wegovy/cost-coverage/initiating-wegovy-pa.html
- NovoCare, Wegovy savings offer: https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- UnitedHealthcare, Wegovy PA criteria (CV indication): https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Non-Formulary-Wegovy.pdf
- KFF, Wegovy Medicare coverage analysis: https://www.kff.org/medicare/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/
- California Medi-Cal, GLP-1 coverage changes January 2026: https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/member/GLP1_Changes.pdf
- Pennsylvania Medicaid, GLP-1 PA criteria: https://www.pa.gov/content/dam/copapwp-pagov/en/dhs/documents/docs/publications/documents/forms-and-pubs-omap/mab2025112403.pdf
- Novo Nordisk / PR Newswire, Medicare GLP-1 Bridge announcement (May 7, 2026): https://www.prnewswire.com/news-releases/wegovy-access-expanded-for-medicare-beneficiaries-living-with-obesity-through-the-medicare-glp-1-bridge-starting-july-1-2026-302764949.html
- Medi-Cal Rx, Wegovy MASH PA removal (April 2026): https://medi-calrx.dhcs.ca.gov/cms/medicalrx/static-assets/documents/provider/2026/04_A_Changes_GLP-1_Drug_Coverage_Wegovy.pdf
- NPR, Patients struggle to pay for obesity drugs as insurance coverage slips (April 2026): https://www.npr.org/2026/04/22/nx-s1-5794613/health-insurance-wegovy-zepbound
